摘要
目的探讨前列腺增生症患者血清中前列腺特异性抗原水平与慢性前列腺炎的关系。方法128例门诊诊断为前列腺增生症的患者,其血清前列腺特异性抗原高于4.0ng/ml且合并慢性前列腺炎;所有患者口服塞来昔布,治疗随访6周;根据治疗后血清前列腺特异性抗原水平及前列腺穿刺活检结果分为三组,观察比较各组治疗前后血清前列腺特异性抗原的水平及前列腺癌诊断阳性率。结果仅治疗后血清前列腺特异性抗原低于4.0ng/ml的一组在治疗前后的水平变化有统计学意义,其余两组均无统计学意义;治疗后前列腺癌诊断阳性率明显高于治疗前。结论对血清前列腺特异性抗原高于4.0ng/ml且合并慢性前列腺炎的前列腺增生患者进行抗炎治疗,既可提高前列腺特异性抗原对前列癌早期诊断的特异性,又可使部分患者避免前列腺穿刺活检造成的痛苦和相关并发症。
Objective: To study the relationship between serum prostate specific antigen (PSA) and chronic prostatitis in patients with benign prostatic hyperplasia (BPH). Methods: There were 128 outpatients who presented with BPH and serum PSA greater than 4.0 ng/ml and were subsequently diagnosed with chronic prostatitis. All patients were treated with a 6-week course of anti-inflammation agent (celecoxib). Patients were divided into three groups according to the levels of serum PSA and the results of prostatic biopsy. Results: There was statistically differences after treatment in the group with serum PSA less than 4.0 ng/ml and not the other two. The positive rate of diagnosis in prostate cancer after treatment was great higher than that before treatment. Conclusions: Patients who are presented with BPH and serum PSA greater than 4.0 ng/ml and are subsequently diagnosed with chronic prostatitis, can be treated with anti-inflammation agent to elevate the specific rate of diagnosis in prostate cancer. Biopsies are not necessary for the patients who are presented with serum PSA less than 4.0 ng/ml.
出处
《中国现代医学杂志》
CAS
CSCD
2004年第10期107-109,共3页
China Journal of Modern Medicine
关键词
前列腺特异性抗原
慢性前列腺炎
prostate specific antigen (PSA)
chronic prostatitis
